Haemophagocytic lymphohistiocytosis (HLH) in Human Immunodeficiency Virus (HIV) infected individuals can either be due to the disease itself or due to associated infections/malignancies. The treatment for HLH requires immunosuppressive therapy but administering immunos uppressive therapy to an already immunosuppressed patient (HIV infection) is complex. We present two such cases of HLH in patients infected with HIV. In the first case, no alternate cause for HLH was found even after extensive investigations and it was attributed to the uncontrolled HIV replication. Patient was started on dexamethasone for the same but succumbed to hospital acquired pneumonia. The second patient was diagnosed with Hod gkin's lymphoma but he succumbed to his illness before initiating immunosuppressive therapy for HLH. We report these cases to highlight the dilemma and a need for further research in this direction.
Introduction
Haemophagocytic lymphohistiocytosis (HLH) is an aggressive syndrome of excessive immune activation. It is diagnosed using the HLH-2004 protocol which requires fulfilling five out of eight criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or low fibrinogen, hyperferritinemia, increased soluble CD25 levels, decreased Natural killer (NK) cell activity and histopathological evidence of hemophagocytosis [1] . Out of these, NK cell activity and serum CD25 levels are not widely available, making the diagnosis of HLH often difficult. This problem becomes more complex in patients with Human Immunodeficiency Virus (HIV) infection as features such as fever, bicytopenia and splenomegaly are already common in these patients with or without presence of opportunistic infections. Once diagnosed, the treatment of such a patient is even more challenging.
The biggest hurdle is the use of immunosuppression for the treatment of HLH in an already immunocompromised person. A balance has to be struck between controlling inflammation with immunosuppressive drugs and limiting the risk of life threatening opportunistic infections.
We present two cases of HIV with HLH to explain our dilemma. With a presumptive diagnosis of tuberculosis, modified anti-tubercular therapy (ATT) (levofloxacin, ethambutol and amikacin) was started as the patient had elevated bilirubin level. There was no response even after one month of ATT. Introduction of rifampicin and isoniazid was attempted but the bilirubin levels rose to 9.5g/dl. Clarithromycin was empirically added to cover for Mycobacterium avium complex (MAC) infection. On further investigations, she was found to have a triglyceride levels of 435 mg/dl, fibrinogen levels of 500 mg/dl, ferritin levels of >2000 ng/ml and decreased NK cell activity. With a diagnosis of Haemophagocytic lymphohistiocytosis (HLH), dexamethasone at a dose of 16 mg per day was started. The fever and pancytopenia improved in a week's time (Hemoglobin-7.4gm/dl, total leucocyte count-5300/cu.mm, platelet count-50,000/cu.mm). The patient was doing well but she started getting dyspneic fifteen days after the initiation of steroids. Chest X-ray revealed consolidation in the right middle lobe. With a diagnosis of hospital acquired pneumonia, she was started on cefoperazone sulbactam, but she succumbed to her illness after two days. Vitamin B12 levels were normal but the folate levels were low (2.2ng/ml). Serum LDH levels were elevated (834 IU/l). developed HLH has been reported [4, 5] . HLH in HIV patient can either be due to the disease itself or because of the opportunistic infections or malignancy associated with HIV [6, 7] . In the first patient, we extensively looked for an opportunistic infection that could have caused the secondary HLH but did not find any. there was no significant difference in survival between those who received HLH specific treatment and those who did not [10] .
Patient and observation

Conclusion
We report these cases to raise a pertinent question regarding the management of HLH in patients with HIV. Although, there is no dearth in availability of triggers in patients with HIV, there is a definite gap in the literature regarding their management. Due to the variability in the nature of these triggers, development of a standard therapeutic protocol is difficult. There is a definite need for further research in this area.
